DE3782439T2 - Dihydropyridin-formulierung mit verzoegerter freigabe. - Google Patents

Dihydropyridin-formulierung mit verzoegerter freigabe.

Info

Publication number
DE3782439T2
DE3782439T2 DE8787101203T DE3782439T DE3782439T2 DE 3782439 T2 DE3782439 T2 DE 3782439T2 DE 8787101203 T DE8787101203 T DE 8787101203T DE 3782439 T DE3782439 T DE 3782439T DE 3782439 T2 DE3782439 T2 DE 3782439T2
Authority
DE
Germany
Prior art keywords
calcium channel
pharmaceutical composition
channel blocker
acting
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787101203T
Other languages
German (de)
English (en)
Other versions
DE3782439D1 (de
Inventor
Michael John Dey
Calum Brechin Macfarlane
Alastair Brereton Selkirk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of DE3782439D1 publication Critical patent/DE3782439D1/de
Application granted granted Critical
Publication of DE3782439T2 publication Critical patent/DE3782439T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE8787101203T 1986-01-30 1987-01-29 Dihydropyridin-formulierung mit verzoegerter freigabe. Expired - Lifetime DE3782439T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82389686A 1986-01-30 1986-01-30
US94087886A 1986-12-10 1986-12-10

Publications (2)

Publication Number Publication Date
DE3782439D1 DE3782439D1 (de) 1992-12-10
DE3782439T2 true DE3782439T2 (de) 1993-05-19

Family

ID=27124769

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787101203T Expired - Lifetime DE3782439T2 (de) 1986-01-30 1987-01-29 Dihydropyridin-formulierung mit verzoegerter freigabe.

Country Status (18)

Country Link
EP (1) EP0231026B1 (enExample)
JP (1) JP2524990B2 (enExample)
KR (1) KR900005009B1 (enExample)
AU (1) AU604672B2 (enExample)
CA (1) CA1285227C (enExample)
DE (1) DE3782439T2 (enExample)
DK (1) DK175216B1 (enExample)
ES (1) ES2052500T3 (enExample)
FI (1) FI88872C (enExample)
GR (1) GR3006148T3 (enExample)
HU (1) HU196709B (enExample)
IE (1) IE61879B1 (enExample)
IL (2) IL81419A0 (enExample)
IT (1) IT1206876B (enExample)
NO (1) NO174325C (enExample)
NZ (1) NZ219090A (enExample)
PH (1) PH26366A (enExample)
PT (1) PT84213B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
GB2209669B (en) * 1987-09-11 1992-02-12 Squibb & Sons Inc Pharmaceutical composition containing high drug load and method for preparing same
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US4925676A (en) * 1989-02-02 1990-05-15 Warner-Lambert Company Extended release gemfibrozil composition
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
JPH0729926B2 (ja) * 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
EP0619731B1 (en) * 1991-12-30 2000-10-04 Fmc Corporation Microcrystalline cellulose spheronization composition
GB9203689D0 (en) * 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
EP0557064B1 (en) * 1992-02-20 1997-06-11 Euroceltique S.A. Modified release formulation
HRP970485A2 (en) * 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
ATE400251T1 (de) 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795766A (fr) * 1972-02-22 1973-08-22 Lilly Co Eli Particules de napsylate de propoxyphene retard et procede de fabrication de ces particules
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation

Also Published As

Publication number Publication date
FI88872C (fi) 1993-07-26
IE61879B1 (en) 1994-11-30
FI870380L (fi) 1987-07-31
NO870368D0 (no) 1987-01-29
IE870229L (en) 1987-07-30
EP0231026B1 (en) 1992-11-04
PT84213B (pt) 1989-03-30
ES2052500T3 (es) 1994-07-16
JP2524990B2 (ja) 1996-08-14
PT84213A (en) 1987-02-01
FI870380A0 (fi) 1987-01-29
NO174325B (no) 1994-01-10
IT1206876B (it) 1989-05-11
AU6810287A (en) 1987-08-06
HUT42950A (en) 1987-09-28
NO870368L (no) 1987-07-31
IL81419A0 (en) 1987-08-31
DK47787A (da) 1987-07-31
DK47787D0 (da) 1987-01-29
NZ219090A (en) 1990-04-26
AU604672B2 (en) 1991-01-03
KR870007121A (ko) 1987-08-17
NO174325C (no) 1994-04-20
JPS62252732A (ja) 1987-11-04
KR900005009B1 (ko) 1990-07-16
EP0231026A1 (en) 1987-08-05
IL81419A (en) 1991-07-18
HU196709B (en) 1989-01-30
PH26366A (en) 1992-06-01
DE3782439D1 (de) 1992-12-10
FI88872B (fi) 1993-04-15
DK175216B1 (da) 2004-07-12
IT8767057A0 (it) 1987-01-29
CA1285227C (en) 1991-06-25
GR3006148T3 (enExample) 1993-06-21

Similar Documents

Publication Publication Date Title
US4940556A (en) Method of preparing long acting formulation
US5198226A (en) Long acting nicardipine hydrochloride formulation
DE69013473T2 (de) Cimetidin enthaltende Arzneimittel.
DE69831869T2 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
DE69423028T3 (de) Zubereitung mit kontrollierter freisetzung, die ein morphinsalz enthält
EP0250267B1 (en) Controlled absorption pharmaceutical composition
DE69231415T2 (de) Stabilisiertes Substrat für kontrollierte Freigabe mit von einer wässerigen Dispersion eines hydrophobischen Polymers abgeleitete Beschichtung
US5576022A (en) Controlled release tacrine drug delivery systems and methods for preparing same
DE69102211T2 (de) Pharmazeutische Zubereitung mit kontrollierter Freigabe.
US5209933A (en) Long acting calcium channel blocker composition
DE3520184C2 (de) Neue galenische Retardform
DE60210552T2 (de) Prozess zur Herstellung einer festen pharmazeutischen Zubereitung welche einen schwerlöslichen Wirkstoff enthält
CH648484A5 (de) Pharmazeutische zubereitung eines festen medikamentmaterials.
EP0231026B1 (en) Sustained-release dihydropyridine formulation
DE3719818C2 (de) Pharmazeutische Zusammensetzung
DE60211769T2 (de) Verfahren zur Herstellung von Arzneistoffgranulatkörnern, die Arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische Zubereitungen
CH705678B1 (de) Verwendung von Bindemitteln zur Herstellung von lagerungsstabilen Formulierungen.
CH705273B1 (de) Pharmazeutische Zusammensetzung – umfassend Hydromorphon und Naloxon.
DE3400106A1 (de) Pharmazeutische zubereitungen mit gesteuerter arzneistoff-freisetzung
DE60308828T2 (de) Orale pharmazeutische Zusammensetzung mit verzögerter Freisetzung
DE60035579T2 (de) Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
DE69002822T2 (de) Pharmazeutische Zubereitung zur oralen Verabreichung in flüssiger Form.
EP3057580B1 (de) Pharmazeutische darreichungsformen enthaltend natrium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olat
CH670201A5 (en) Solid dispersions of water-insol. drugs - comprising coherent crystals of drug in water-soluble matrix
DE3708068A1 (de) Pharmazeutische zusammensetzung, die vinburnin enthaelt, verfahren zu ihrer herstellung und ihre verwendung zur therapie cerebrovaskulaerer erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Free format text: BARZ, P., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 80803 MUENCHEN